학술논문
Redo Pelvic Surgery and Combined Metastectomy for Locally Recurrent Rectal Cancer with Known Oligometastatic Disease: A Multicentre Review.
Document Type
Article
Author
Keogh, Cian; O'Sullivan, Niall J.; Temperley, Hugo C.; Flood, Michael P.; Ting, Pascallina; Walsh, Camille; Waters, Peadar; Ryan, Éanna J.; Conneely, John B.; Edmundson, Aleksandra; Larkin, John O.; McCormick, Jacob J.; Mehigan, Brian J.; Taylor, David; Warrier, Satish; McCormick, Paul H.; Soucisse, Mikael L.; Harris, Craig A.; Heriot, Alexander G.; Kelly, Michael E.
Source
Subject
*RESEARCH
*PERIOPERATIVE care
*PELVIC exenteration
*COUNSELING
*CANCER relapse
*RETROSPECTIVE studies
*ACQUISITION of data
*DISEASES
*TUMOR classification
*TREATMENT effectiveness
*REOPERATION
*MEDICAL records
*DESCRIPTIVE statistics
*COMBINED modality therapy
*PROGRESSION-free survival
*METASTASECTOMY
*OVERALL survival
RECTUM tumors
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
*
Language
ISSN
2072-6694
Abstract
Simple Summary: Due to advancements in surgical techniques, patients with recurrent rectal cancer and liver or lung secondaries are being increasingly considered for aggressive surgery. Our study reports outcomes for patients within this category undergoing simultaneous surgical removal of their cancer recurrence and secondaries across four centres worldwide. Our findings show that this option is feasible in a highly motivated group of patients who are well counselled on potential outcomes, including a high risk of cancer recurrence. Introduction: Historically, surgical resection for patients with locally recurrent rectal cancer (LRRC) had been reserved for those without metastatic disease. 'Selective' patients with limited oligometastatic disease (OMD) (involving the liver and/or lung) are now increasingly being considered for resection, with favourable five-year survival rates. Methods: A retrospective analysis of consecutive patients undergoing multi-visceral pelvic resection of LRRC with their oligometastatic disease between 1 January 2015 and 31 August 2021 across four centres worldwide was performed. The data collected included disease characteristics, neoadjuvant therapy details, perioperative and oncological outcomes. Results: Fourteen participants with a mean age of 59 years were included. There was a female preponderance (n = 9). Nine patients had liver metastases, four had lung metastases and one had both lung and liver disease. The mean number of metastatic tumours was 1.5 +/− 0.85. R0 margins were obtained in 71.4% (n = 10) and 100% (n = 14) of pelvic exenteration and oligometastatic disease surgeries, respectively. Mean lymph node yield was 11.6 +/− 6.9 nodes, with positive nodes being found in 28.6% (n = 4) of cases. A single major morbidity was reported, with no perioperative deaths. At follow-up, the median disease-free survival and overall survival were 12.3 months (IQR 4.5–17.5 months) and 25.9 months (IQR 6.2–39.7 months), respectively. Conclusions: Performing radical multi-visceral surgery for LRRC and distant oligometastatic disease appears to be feasible in appropriately selected patients that underwent good perioperative counselling. [ABSTRACT FROM AUTHOR]